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 ABSTRACT 
Aims: ApoC-III is an important novel target underpinning the link between hypertriglyceridemia with 
cardiovascular disease. Here, we investigated how apoC-III metabolism is altered in subjects with 
type 2 diabetes, and focused on whether the perturbed plasma triglyceride concentrations in this 
condition are determined primarily by the secretion rate or the removal rate of this apoprotein. 
Second, we investigated whether improvement of glycemic control using the GLP-1 analogue 
liraglutide for 16 weeks modifies apoC-III dynamics. 
Materials and methods: Postprandial apoC-III kinetics were assessed after a bolus injection of 
[5,5,5-
2
H3]leucine, using ultrasensitive mass spectrometry techniques. We compared apoC-III kinetics 
in two situations; in subjects with type 2 diabetes subjects before and after liraglutide therapy, and in 
type 2 diabetic and BMI-matched non-diabetic subjects. Liver fat content, subcutaneous abdominal 
and intra-abdominal fat were determined using proton magnetic resonance spectroscopy. 
Results: Improved glycemic control by liraglutide therapy for 16 weeks reduced significantly apoC-
III secretion rate (561±198 vs. 652±196 mg/day, p=0.03) and apoC-III levels (10.0±3.8 vs. 11.7±4.3 
mg/dL, p=0.035) in type 2 diabetic subjects. Change in apoC-III secretion rate was associated 
significantly with the improvement in indices of glucose control (r=0.67; p=0.009) and change in 
triglyceride AUC (r=0.59; p=0.025). In line, the apoC-III secretion rate was higher in subjects with 
type 2 diabetes compared with BMI-matched non-diabetic subjects (676±208 vs. 505±174 mg/day, 
p=0.042).  
Conclusions: The results reveal that the secretion rate of apoC-III associates with elevation of 
triglyceride-rich lipoproteins in type 2 diabetics, potentially through the influence of glucose 
homeostasis on the production of apoC-III.  
Keywords: apoC-III; kinetics; lipoproteins; stable isotopes; type 2 diabetes 
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 INTRODUCTION 
Apolipoprotein C-III (apoC-III) is increasingly recognized as an important determinant of 
hypertriglyceridemia and a risk factor for cardiovascular disease (CVD)
1-4
. ApoC-III also 
substantially improves the prediction of CVD in type 2 diabetes beyond that obtained with the 
variables used in the Framingham risk score
5
. Loss of function mutations in the gene encoding apoC-
III (APOC3) is associated with low triglyceride levels
6,7
, and a decreased risk for CVD while 
overexpression of APOC3 is associated with hypertriglyceridemia
8
. These results have identified 
apoC-III as an emerging target linking hypertriglyceridemia with cardiovascular disease, and clinical 
trials on apoC-III antisense oligonucleotides designed to inhibit synthesis of the apoprotein are in 
progress
9
. 
ApoC-III is a small apoprotein that is mainly secreted from the liver on very low-density lipoprotein 
(VLDL) particles and to a lesser degree from the intestine on chylomicrons. In the circulation, apoC-
III is continuously exchanged between different lipoprotein particles and significant amounts of apoC-
III are carried not only on VLDL but also on low- and high-density lipoprotein (LDL and HDL) 
particles
10,11
. The distribution of apoC-III between different lipoprotein fractions is dependent on the 
metabolic state, varying between the fasting and postprandial states and between subjects with normal 
and high plasma triglyceride levels
11-14
. The impact of apoC-III on CVD risk is complex but in 
general, lipoproteins with high apoC-III seem to be highly atherogenic
2,15,16
. 
ApoC-III has multiple actions on lipid metabolism as well as on proinflammatory and atherogenic 
processes
12-14
. It is well known as an inhibitor of lipoprotein lipase (LPL), the rate-limiting enzyme in 
the lipolytic process
17-19
, and more recent data indicate that it also impairs the uptake of lipoprotein 
remnants by the liver
20-23
. We have earlier reported that plasma triglyceride concentrations in 
abdominal obesity are determined by the kinetics of VLDL1 subspecies, catabolism being mainly 
dependent on apoC-III concentration 
24
. In addition, overexpression of apoC-III has been reported to 
promote VLDL assembly and secretion in hepatocytes in vitro and in genetically modified mice
25,26
; 
however, it is not known if this also occurs in humans. 
Promoter analysis of APOC3 identified binding sites for transcription factors including the 
carbohydrate response element binding protein (ChREBP)
27
, which led to the proposal that glucose and 
plasma triglyceride metabolism are linked via the regulation of APOC3 expression
12
. APOC3 
expression is upregulated by glucose and downregulated by insulin, and it has been suggested that the 
glucose-mediated expression of APOC3 may contribute to lower lipolysis and to an increase in 
peripheral glucose handling
27-30
. In addition, the inhibitory effect of insulin on APOC3 expression is 
lost when insulin signaling is impaired, which may explain why apoC-III concentrations are high in 
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 insulin-resistant states such as obesity, the metabolic syndrome, type 2 diabetes, and 
hypertriglyceridemia
15,27,31
. 
Glucagon-like peptide-1 (GLP-1) agonists have been shown to improve postprandial lipid 
metabolism.
32,33
 In line, we reported that liraglutide therapy for 16 weeks improved multiple 
cardiometabolic risk factors, inducing a reduction in plasma apoC-III
34
. It was estimated, that the 
decrease in fasting and postprandial levels of apoC-III during liragutide therapy explained about 50% 
of the observed reduction in postprandial triglyceride, RLP-cholesterol and TRL-cholesterol. These 
observations prompted us to perform apoC-III kinetic studies before and after liraglutide therapy  
In this study, we investigated for the first time how the dynamics of apoC-III metabolism are altered 
in subjects with type 2 diabetes, and focused on whether plasma triglyceride concentrations are 
determined by the secretion rate or the removal rate of apoC-III. Second, we investigated whether 
improvement of glycemic control using GLP-1 analogue liraglutide for 16 weeks modifies apoC-III 
dynamics. 
METHODS 
Study cohort The current study is an extension of a previously reported intervention protocol to 
examine the effects of the GLP-1 analogue liraglutide 1.8 g daily for 16 weeks on glycaemia, ectopic 
fat depots and cardiometabolic risk factors
34
. Details of the recruitment of subjects are previously 
reported
34
. Here we analyzed whether improved glycemic control in subjects with type 2 diabetes 
effects apoC-III kinetics. We included 14 obese men [waist >92 cm, body mass index (BMI) 27–40 
kg/m
2
] with type 2 diabetes who had HbA1c 42–75 mmol/l (6–9%) and who completed the 
intervention period with liraglutide. To explore the effect of type 2 diabetes on apoC-III kinetics, we 
were able to identify from our previous kinetic studies
35
 11 obese men without type 2 diabetes 
matched for age and BMI as non-diabetic comparators for 11 (out of the 14) subjects with type 2 
diabetes. Additional inclusion criteria were age 30–75 years, triglycerides 1.0–4.0 mmol/l and LDL-
cholesterol <4.5 mmol/l. All those with type 2 diabetes used stable daily doses of metformin (between 
1.0–3.0 g/ day) and statin throughout the study period34. Exclusion criteria for all subjects were: age 
<30 years or >75 years, smoking, alcohol consumption over 2 units/day (i.e., 20 g pure alcohol), 
cardiovascular disease, hormonal therapy, use of fibrates and fish oils, hepatic and renal diseases, 
eGFR <60 ml/min, gastroenterological, thyroid or hematological abnormalities, and any chronic 
disease requiring medication except for controlled hypertension. The study protocol was approved by 
the ethics committees of Helsinki University Hospital and the national Agency of Medicines, 
Helsinki, Finland (Eudra CT 2013-005075-40, Clinical Trials NCT 92765399). Each subject gave 
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 written informed consent before participation in the study. All studies were performed in accordance 
with the Declaration of Helsinki for clinical trials.  
Study design—The actual protocol included two separate visits within a 1-week period: (1) a 
postprandial apoC-III kinetic study using stable isotopes, and (2) determination of abdominal fat 
depots and liver fat content. These tests were repeated in the liraglutide intervention group after 16 
weeks liraglutide treatment. 
Postprandial kinetic study: The subjects were admitted at 7:30 am after an overnight fast and baseline 
blood samples were taken. At 8:00 am, a bolus injection of [5,5,5-
2
H3]leucine [7 mg/kg] was given 
and blood was drawn during the 2 h after the injection as described previously
36
.Two hours after the 
bolus injection, the subjects received a fat-rich meal served with a cocoa-fat rich emulsion containing 
40 g of olive oil (Amway, Firenze). The meal consisted of bread, cheese, ham, boiled eggs, fresh red 
pepper, low-fat (1%) milk, orange juice and tea or coffee. Altogether, the meal contained 63 g 
carbohydrate, 69 g fat and 40 g protein, and was consumed within 10 min. Blood samples were taken 
at 0.5, 1, 2, 3, 4, 6, 8 and 10 hrs. after the meal. Water was allowed ad libitum and the subjects 
remained physically inactive. 
Determination of intra-abdominal fat depots: Proton magnetic resonance spectroscopy was performed 
using a 1.5-T whole-body device to determine liver fat content
37,38
, as well as subcutaneous 
abdominal and intra-abdominal fat
39
. All analyses of the imaging results were performed by one 
person (AH). Subjects were advised to fast for 4 h before imaging.  
Analysis of hepatic de novo lipogenesis (DNL)—The DNL analyzed at 0 h and was calculated from 
enrichment of deuterated water ingested during the kinetic study at the specified time points 
40
. 
Isolation of lipoprotein fractions—Lipoprotein fractions [chylomicrons (Sf >400), large VLDL1 
particles (Sf 60–400) and smaller VLDL2 particles (Sf 20–60)] from all serum samples drawn during 
the postprandial apoC-III kinetic study, were separated by density gradient ultracentrifugation
41
. 
Biochemical analysis—Triglyceride and cholesterol concentrations in total plasma and lipoprotein 
fractions as well as in triglyceride-rich lipoprotein (TRL) cholesterol and remnant-lipoprotein (RLP) 
cholesterol were analyzed using assays (Denka Seiken, Tokyo, Japan) and the Konelab 60i analyzer 
(Thermo Fisher, USA). RLP-C captures lipoproteins not binding with anti-apoA-I and anti-apoB-100 
as remnant lipoproteins
42
. The TRL-C quantifies cholesterol in both chylomicron remnants, and 
VLDL-IDL particles. Fasting and postprandial apoB48 levels in total plasma were measured by 
ELISA (Shibayagi, Shibukawa, Japan). Concentrations of plasma glucose and insulin were measured 
with hexokinase method (Roche Diagnostic Gluco-quant, Germany) and electrochemiluminescence 
(Roche sandwich immunoassay on a Cobas autoanalyzer), respectively. Plasma levels of apoC-III 
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 were measured immunoturbidometrically (Kamiya Biomedical Company, Seattle, WA) and β-
hydroxybutyrate concentrations were measured by an enzymatic method with β-hydroxybutyrate FS 
kit (DiaSys Diagnostic Systems, Holzheim, Germany) on a Konelab 60i analyzer.  
Calculation of estimated GFR (eGFR)—Estimated Glomerular filtration rate (eGFR) was estimated 
using the revised Lund-Malmö equations based on age, gender and creatinine
43
. 
Kinetic analysis—Tracer kinetics ([5,5,5-2H3]leucine) of apoC-III was modelled using an established 
model including a four compartment system for free leucine kinetics coupled to a delay compartment 
representing synthesis and secretion of apoC-III
44
 (see details in on-line Supplementary information). 
The kinetic model was implemented as a population kinetic model in Monolix (version 2016R1. 
Antony, France: Lixoft SAS, 2018). All model parameters were assumed to be log-normally 
distributed. Individual parameters were calculated using conditional means using Monolix. Further 
details of the implementation are given in the on-line Supplementary information. 
Statistical analysis—Statistical analyses were performed with R (R Foundation for Statistical 
Programming, www.r-project.org) version 3.2.1 and GraphPad Prism version 7 (La Jolla, CA). Data 
are presented in tables as mean ± SD and in figures as mean ± SE. We calculated the area under the 
curve (AUC) using the trapezoidal rule between 0 and 8 hours after the meal. Subjects with and 
without type 2 diabetes were compared using Mann-Whitney U-test, unless stated otherwise. P-values 
<0.05 were considered statistically significant and were not adjusted for multiple testing. 
RESULTS  
Effects of liraglutide therapy on apoC-III metabolism  
We tested the hypothesis that improved glycemic control would affect apoC-III metabolism in type 2 
diabetic subjects. We have recently reported effects of liraglutide treatment on glycemic control, fat 
depots as well as fasting and postprandial lipids in type 2 diabetic subjects
34
. Characteristics of these 
14 individuals are summarized in Suppl. Table S1, and postprandial responses are summarized in 
Suppl. Table S2. Overall liraglutide therapy was associated with beneficial changes of atherogenic 
lipids/ lipoproteins and apoC-III level (Suppl. Table 1 and 2). Notably, apoC-III response 
(postprandial AUC) was reduced by 13% during liraglutide therapy. This raises the question what are 
the factors driving these changes. ApoC-III secretion rate and apoC-III plasma concentration, but not 
apoC-III fractional catabolic rate, correlated strongly with the plasma triglyceride concentration 
(Suppl. Figure 1).  The data suggest that the secretion rate of apoC-III is a major determinant for the 
concentration of plasma triglycerides. 
Treatment with liraglutide resulted in a significant decrease in fasting apoC-III concentration (-14%; 
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 11.7±4.3 mg/ dl vs 10.0±3.8 mg/ dl, p<0.05). Examining the enrichment curves, it was observed that 
there was a similar decay rate for the tracer in apoC-III in both treatment periods (Suppl. Figure S2) 
and this was reflected in the lack of change in FCR (Figure 1 and Table 1). Accordingly, the 
decreased pool was attributable to a 13% decrease in apoC-III synthesis (6.6±1.7 mg/kg/day on 
placebo vs 5.8±2.0 mg/kg/day on liraglutide, p<0.05). Indeed, apoC-III SR turned out to be the major 
predictor of plasma apoC-III pool both before and after liraglutide therapy in these type 2 diabetic 
subjects (r>0.83; p<0.001). Further, changes of apoC-III secretion rate and apoC-III pool size 
correlated with those of plasma TG AUC (Figure 2 E and F). 
It was also noteworthy that there were significant associations during liraglutide therapy, between 
changes in parameters of glycemic control and apoC-III SR (r=0.67; p=0.009) and pool-size (r=0.75; 
p=0.002) in the Type 2 diabetic subjects (Figure 2). In contrast, there was no significant association 
between changes in parameters of glycemic control and apoC-III FCR (r=0.40; p=0.15) (Suppl. 
Figure 3).  
Effects of type 2 diabetes on apoC-III kinetics 
To explore the effect of type 2 diabetes on apoC-III kinetics, we were able to identify from our 
previous kinetic studies
35
 11 obese men without type 2 diabetes matched for age and BMI as non-
diabetic comparators for 11 (out of the 14) subjects with type 2 diabetes. Baseline data and 
biochemical measures of the 11 men with type 2 diabetes and the non-diabetic subjects are shown in 
Table 2. All were abdominally obese and the two groups were well matched for age, BMI and waist 
circumference. In the diabetic group duration of diabetes averaged 6.6 years while parameters of 
glycemic control (i.e., glucose and HbA1C) indicated that acceptable glycemic control had been 
achieved. Plasma triglyceride levels were not significantly higher in the men with type 2 diabetes. 
Total cholesterol, and LDL- and TRL-cholesterol concentrations were, as expected, lower in the men 
with type 2 diabetes since these subjects were all on statin therapy. The diabetic group had 2.6-fold 
higher liver fat content and 3.4-fold higher DNL than in the non-diabetic subjects; β-hydroxybutyrate, 
a surrogate marker of hepatic β-oxidation, was similar in the two groups (Table 2). 
Postprandial triglyceride responses to the test meal in plasma, chylomicrons, VLDL1 and VLDL2 
fractions were analyzed in the two groups (Suppl. Figure S4). Despite comparable triglyceride levels 
at baseline and at early time points after the meal in the two groups, the triglyceride values 8 h after 
the meal were markedly higher in the group with type 2 diabetes. Plasma fasting apoC-III showed a 
wide range in both groups (non-diabetic comparator group, 2.8–13.7 mg/dl; type 2 diabetes, 3.2–17.7 
mg/dl), and postprandial apoC-III concentrations showed a non-significant trend to be higher in the 
group with type 2 diabetes (Suppl. Figure S4).  
This article is protected by copyright. All rights reserved
A
cc
ep
te
d 
A
rti
cl
e
 Kinetic parameters (secretion rate and fractional catabolic rate) for plasma apoC-III (Table 1) were 
compared in the 2 groups. During the evaluation period apoC-III levels were in steady state (Suppl. 
Figure S4). Mean tracer enrichment curves exhibited a steeper rise and fall in the diabetic group 
(Suppl. Figure S2) than in non-diabetic comparator group, and this translated into a 39% higher 
apoC-III secretion rate and a 17% higher fractional catabolic rate in the former versus the latter 
subjects.  
Consequently, no significant difference was observed in the model-predicted apoC-III pool (Table 1). 
A strong positive correlation between the apoC-III secretion rate and circulating apoC-III pool existed 
across all subjects but there was no significant correlation between the apoC-III fractional catabolic 
rate and the apoC-III pool (Suppl. Figure 5). These results indicate that apoC-III secretion rate is an 
important determinant of plasma apoC-III concentration.  
Relationships between plasma apoC-III kinetics and metabolic parameters  
Strong positive correlations existed between fasting plasma triglycerides and both the apoC-III level 
(r= 0.83, p<0.001) and secretion rate (r=0.9, p<0.001) in the combined group of obese type 2 diabetic 
and non-diabetic subjects. However, no significant relationship was observed between the apoC-III 
fractional catabolic rate and plasma triglycerides (r=0.002; p=0.9), see Suppl. Figure S1. The data 
further reinforce that the secretion rate of apoC-III strongly associates with the concentration of 
plasma triglycerides. Interestingly, a positive correlation was observed between the apoC-III FCR rate 
and DNL in VLDL1 (r= 0.55, p<0.01). We also observed a positive correlation between HbA1c and 
DNL in VLDL1 (r=0.45, p< 0.05) and a negative correlation between insulin and DNL in VLDL1 (r= 
-0.56, p<0.01). Plasma fasting TRL-cholesterol concentrations correlated positively with plasma 
apoC-III concentrations (r=0.48, p<0.05), and plasma RLP-cholesterol concentration correlated with 
the apoC-III secretion rate and apoC-III concentrations (r=0.49, p<0.05 and r=0.54, p<0.01 
respectively). 
Significant correlations were also found between indices of glycemic control and apoC-III kinetic 
measures. HbA1C and fasting glucose correlated positively with apoC-III secretion rate (Figure 1 and 
Suppl. Figure 5). HbA1C (r=0.63, p<0.01), fasting glucose (r=0.47, p<0.05) and insulin (r=0.57, 
p<0.05), correlated also positively with apoC-III fractional catabolic rate (Figure 1 and Suppl. 
Figure 5). 
 
DISCUSSION 
Here, we report that apoC-III metabolism is significantly perturbed in subjects with type 2 diabetes. 
The apoC-III secretion rate was markedly higher in subjects with diabetes compared with BMI-
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 matched non-diabetic subjects. Improved glycemic control with liraglutide therapy reduced 
significantly apoC-III secretion rate and, thereby, apoC-III levels in type 2 diabetic subjects. These 
findings suggest that glucose homeostasis is a regulator of apoC-III metabolism, and that the secretion 
rate of apoC-III seems to be an important driver for the elevation of TRLs in type 2 diabetes. 
Several investigators have reported elevation of plasma apoC-III in subjects with type 2 diabetes
12
, 
and we designed our study to gain insight into the dynamics of apoC-III metabolism in this condition. 
We recruited subjects who were treated with metformin only and had satisfactory glycemic control to 
avoid marked diabetic hypertriglyceridemia. Both groups of diabetic and non-diabetic men were 
obese with similar BMI and waist circumference, and plasma triglycerides and apoC-III levels only 
showed a trend to be elevated in the group with type 2 diabetes. However, in line with previous data
45
 
we observed a positive correlation between plasma triglycerides and apoC-III levels in the combined 
cohort as well as in the liraglutide intervention study. Likewise, the changes of triglycerides and TRL 
responses during OFTT correlated with the observed changes of apoC-III responses highlighting the 
role of apoC-III as a regulator of not only plasma triglycerides but also atherogenic remnants particles 
that are known to be increased in diabetic dyslipidemia
12,46
. Several studies have also reported a close 
correlation between VLDL triglycerides and VLDL apoC-III secretion rates
47-51
. Thus, the data are 
consistent with the previously observed close relationship between apoC-III and triglyceride and 
remnant levels at the population level in subjects both with and without type 2 diabetes
3,11,12,31,45,51,52
.  
One of the aims of our study was to investigate factors that regulate apoC-III secretion rate and/or 
fractional catabolic rate. Glucose, insulin and free fatty acids are reported to modulate apoC-III 
expression
13,30
. Carron et al reported that both glucose and insulin regulate apoC-III transcription but 
in opposite ways and they proposed that the dysregulation of apoC-III is a critical factor to explain the 
dyslipidemia in insulin-resistant states
27
. We observed some positive correlations between measures 
of glucose homeostasis and apoC-III secretion rate in the cross-sectional study. Furthermore, the 
changes of glycemic parameters during liraglutide therapy correlated with changes of apoC-III 
secretion reinforcing the role of glycemic control as a determinant of apoC-III secretion rate. Notably, 
the effect of glucose on apoC-III expression in hepatocytes has in vitro been shown to be mediated by 
carbohydrate responsive element binding protein and HNF4α genes30. Thus, the effects of liraglutide 
therapy seem to be linked to improved glycemic control. Direct effects of liraglutide on liver cells 
seem less likely since several studies have failed to confirm the expression of the canonical GLP-1R 
in hepatocytes
30,53,54
. Therefore, many actions by GLP-1 agonists are likely indirectly mediated, 
possibly through neural circuits. 
Unexpectedly, the apoC-III catabolic rate was also significantly higher in the men with type 2 
diabetes in our cross-sectional study. We cannot exclude the possibility that this effect was caused by 
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 the statin therapy leading to increased LDL receptor dependent removal of lipoproteins. However, 
liraglutide therapy did not influence apoC-III catabolic rate in our intervention study. This finding 
indicates that the effect of liraglutide on apoC-III secretion rate is probably not explained by statin 
treatment. Still, the effect of statins on apoC-III metabolism remains to be fully clarified in larger 
studies
55
.  
Interestingly, the measures of glycemic control correlated positively with apoC-III clearance rate. The 
major organ for apoC-III clearance seems to be the kidney, which is responsible for the removal of 
free (i.e. non-lipoprotein associated) apoC-III molecules
56
. We therefore estimated the glomerular 
filtration rate in subjects with and without type 2 diabetes but did not find any significant difference, 
which is not surprising since subjects with kidney disease, were excluded from the study. This raises 
the question why impaired glycemic control correlates with increased apoC-III clearance? One 
possibility could be that the different sialylated isoforms of apoC-III have different clearance 
pathways, as Mauger et al have reported different clearance kinetics of the apoC-III isoforms
57
. In 
line, changes in apoC-III glycoisoform ratios have been observed in kidney diseases
58,59
.  
The role of apoC-III in atherogenesis has attracted major interest during recent years. The finding that  
glucose regulates ApoC3 expression raises the role of apoC-III in cardiovascular risk in diabetes. 
Diabetic dyslipidemia is characterized by hypertriglyceridemia and accumulation of remnant 
particles, and apoC-III may aggravate the hypertriglyceridemia by impairing the lipolysis of 
triglyceride-rich lipoproteins. In addition, our results indicate that apoC-III also affect the removal of 
remnant particles, resulting in accumulation of atherogenic remnant particles
60,61
. This may explain 
the improved postprandial lipemia and robust reduction of surrogate markers of remnant particles 
during liraglutide therapy. Thus, our findings highlight the importance of optimal glycemic control in 
Type 2 diabetic subjects with dyslipidemia and high cardiovascular risk. 
Our study has several strengths. First, the study-design enabled us for the first time to estimate kinetic 
parameters of apoC-III using stable isotopes in subjects with type 2 diabetes. Second, the quantification 
of apoC-III enrichment using PRM on a high resolution/accurate mass instrument resulted in high 
specificity and sensitivity. In earlier studies using stable isotopes to study apoC-III kinetics, only apoC-
III1 was investigated because of its greater concentration in plasma
44
. Notably, the observed 
correlations were demonstrated using both the cross-sectional cohorts and  in the intervention study 
where the relationship was  enforced by the correlations between changes of glycemic parameters and 
apoC-III secretion rate observed during liraglutide therapy that improved glycemic control.  
However, the study has also weaknesses. We examined a small number of study subjects because of 
the complex methodology for analyzing enrichment of apoC-III. Therefore, we analyzed correlations 
with the total plasma apoC-III instead of analyzing apoC-III in all lipoprotein fractions. This may be a 
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 limitation given that apoC-III exchanges between different lipoprotein fractions, and this may result in 
different clearance rates
47
. However, the Mendelian randomization studies that demonstrated the link 
between apoC-III and CVD were performed using total plasma apoC-III levels
6,7
. In addition, this is a 
pilot study and the results are hypothesis generating and need to be validated in future studies. The 
subjects with type 2 diabetes received statin treatment during the study since ethical considerations 
prohibited us from statin withdrawal during the study. Critically, statin treatment was maintained 
constant during the study. Statin treatment has been shown to lower plasma apoC-III levels 
55,62
. Thus, 
statin treatment of the type 2 diabetic subjects would likely offset the real differences (i.e., it’s 
predictable that off statins the changes of apoC-III concentrations would have been more 
pronounced). 
In summary, the present study points toward a key role of glycemic control in the metabolism of apoC-
III and consequently in the pathophysiology of dyslipidemia in type 2 diabetic subjects. Future studies 
are important to verify the results and to test the concept that apoC-III synthesis may be an attractive 
therapeutic target to reduce the residual risk in particular in type 2 diabetic subjects with abnormal 
TRL metabolism to reduce the burden of CVD.  
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 FIGURE LEGENDS 
Figure 1. Individual apoC-III kinetic parameters before and after liraglutide treatment. (A) apoC-III 
secretion rate was decreased, (B) apoC-III fractional catabolic rate was unchanged and, (C) the apoC-
III pool size was decreased (see Suppl. Table S1 for measured concentration). See Table 1 for mean 
and SD values. Secretion rate, SR; fractional catabolic rate, FCR. 
a
estimated average apoC-III 
concentration. 
Figure 2. Relation between changes in kinetic parameters and changes in glucose and glucose control. 
(A) apoC-III SR vs plasma glucose, (B) apoC-III pool vs plasma glucose, (C) apoC-III SR vs HbA1c, 
(D) apoC-III pool vs HbA1C, (E) apoC-III SR vs plasma TG AUC, and (F) apoC-III pool vs plasma 
TG AUC. Secretion rate, SR; fractional catabolic rate, FCR. 
a
estimated average apoC-III 
concentration. Linear regressions are represented by solid lines. Dashed lines represent 95% CI for 
regression. SR, Secretion rate; FCR, fractional catabolic rate; AUC, area under the curve; TG, plasma 
triglycerides. 
Figure 3. Correlations between (A) apoC-III secretions rate and (B) apoC-III fractional catabolic rate 
and apoC-III plasma concentration. Correlations between HbA1c and (C) apoC-III secretions rate and 
(D) apoC-III fractional catabolic rate in subjects without () and with type 2 diabetes (). Linear 
regressions are represented by solid lines. Dashed lines represent 95% CI for regression. SR, 
Secretion rate; FCR, fractional catabolic rate. 
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Table 1. ApoC-III kinetics in the postprandial period in subjects with type 2 diabetes before and after 
treatment with liraglutide 
 
 
Before liraglutide 
intervention 
During liraglutide 
intervention 
Change 
 
Kinetic parameters mean SD Range mean SD Range % 
p-
value 
ApoC-III SR (mg/kg/day) 6.6 1.7 3.9–10.1 5.8 2.0 2.7–10.8 -12.0 0.030 
ApoC-III SR (mg/day) 652 196 380–1045 561 198 245–1091 -14 0.022 
ApoC-III FCR (pools/day) 1.2 0.1 1.1–1.5 1.2 0.2 1.0–1.5 2.2 0.397 
ApoC-III (mg/dl)a 12.4 3.7 6.0–18.7 10.7 3.7 3.9–18.1 -13.1 0.030 
 
a
 Estimated average apoC-III concentration; Secretion rate, SR; fractional catabolic rate, FCR. 
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 Table 2. Biochemical measures and apoC-III kinetic parameters in non-diabetic subjects and subjects 
with type 2 diabetes 
 
 
 
Non-diabetic  
(n=11) 
Type 2 diabetes  
(n=11)  
 
mean SD Range mean SD Range p-value 
Age, years 58.7 5.6 46–65 60.5 6.1 47–68 0.533 
Diabetes duration, years 
  
 6.6 4.0 2–15 – 
Weight, kg 102.5 11.8 90.6–124.2 100.3 10.5 81.4–114.4 0.818 
Waist, cm 111.5 7.1 101.0–124.5 114.1 7.7 102.5–130.5 0.577 
BMI, kg/m2 30.4 2.8 26.7–33.9 31.9 3.7 26.8–37.8 0.309 
Liver fat, % 6.06 5.13 0.6–16.7 15.49 7.77 3.7–32.8 0.004 
Intra–abdominal fat, cm3 3174 955 1877–4944 3454 1065 2612–6372 0.376 
Subcutaneous fat, cm3 3783 1025 1820–5541 3933 1172 2399–5972 0.670 
eGFR, ml/min/1,73 m2 69.9 3.2 66.3–76.9 68.9 3.5 64.5–76–4 0.224 
3–OHB, mg/dl 1.17 0.70 0.6–2.5 1.40 1.30 0.5–4.9 0.718 
DNL, µmol/l 5.6 5.3 0–15.7 19.0 8.4 5.8–30.6 p<0.001 
Glucose homeostasis        
P–glucose, mmol/l 5.66 0.36 5.1–6.3 9.35 2.52 6.5–13.5 p<0.001 
P–insulin, μIU/mL 10.7 6.5 4.3–25.2 19.2 9.1 10.7–43.6 p<0.001 
HbA1C, % 5.55 0.25 5.0–5.9 6.89 0.73 6.0–8.3 p<0.001 
HbA1C, mmol/mol 37.0 2.7 31.0–40.9 52.8 8.0 42.0–67.3 p<0.001 
Matsuda index 4.6 2.3 2.1–10.4 2.28 140 1.05–5.9 0.003 
HOMA2‐IR 1.41 0.86 0.58–3.36 2.34 0.73 1.06–3.42 0.02 
Lipids and lipoproteins        
Triglycerides, mmol/l 1.48 0.54 0.7–2.4 1.90 0.73 0.9–3.0 0.200 
Cholesterol, mmol/l 5.19 0.68 3.7–6.2 3.89 0.79 2.7–5.5 0.002 
LDL-C, mmol/l 3.59 0.64 2.6–4.5 2.13 0.79 0.8–3.5 p<0.001 
HDL-C, mmol/l 1.10 0.41 0.6–2.1 1.13 0.24 0.7–1.5 0.577 
TRL-cholesterol, mg/dl 33.5 12.2 12.6–55.0 22.5 8.3 7.4–36.4 0.023 
RLP-cholesterol, mg/dl 9.1 6.0 2.5–25.1 8.3 3.0 2.3–16.4 0.818 
ApoAI, mg/dl 138.6 30.1 86–190 122.4 13.7 99.8–146 0.139 
ApoC-III, mg/dla 10.29 2.97 3.5–13.5 11.79 4.70 3.2–17.7 0.140 
Kinetic parameters        
ApoC-III SR (mg/kg/day) 4.87 1.34 2.6–6.6 6.75 1.91 3.8–9.7 0.007 
ApoC-III SR (mg/day) 505 174 266–806 676 208 382–1114 0.042 
ApoC-III FCR (pools/day) 1.05 0.17 0.76–1.33 1.23 0.16 1.04–1.46 0.019 
ApoC-III (mg/dl)b 10.47 2.80 4.76–14.7 12.58 4.24 5.8–18.6 0.10 
 
Biochemical measures were analyzed in fasting samples, and the apoC-III kinetics in the postprandial 
period. 
a
 measured apoC-III concentration at baseline; 
b
 estimated average apoC-III concentration; 
Secretion rate, SR; fractional catabolic rate, FCR.  
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 Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
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